MedTrace Logo

ProSpecTive sAmpling in dRiver muTation Pulmonary Oncology Patients on Tyrosine Kinase Inhibitors (START-TKI)

NCT05221372 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1300

Last updated 2022-02-18

No results posted yet for this study

Summary

The study is perfomed with adult patients with non-small cell lung cancer treated with tyrosine kinase inhibitor. The objective is to collect repeated samples of blood from patients (starting) on a tyrosine kinase inhibitor, for liquid mutation testing, and pharmacokinetic analysis.

Conditions

  • Non Small Cell Lung Cancer
  • Liquid Biopsy
  • Tyrosine Kinase Inhibitor

Sponsors & Collaborators

Principal Investigators

  • Anne-Marie Dingemans, MD, PhD · Erasmus Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-02
Primary Completion
2031-01-01
Completion
2031-01-01

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05221372 on ClinicalTrials.gov